LEQVIO Drug Patent Profile

Which patents cover Leqvio, and what generic alternatives are available?

Leqvio is a drug marketed by Novartis and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-six patent family members in thirty-two countries.

The generic ingredient in LEQVIO is inclisiran sodium. One supplier is listed for this compound. Additional details are available on the inclisiran sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Leqvio

Leqvio was eligible for patent challenges on December 22, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 18, 2034. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LEQVIO

International Patents:	176
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
Drug Prices:	Drug price information for LEQVIO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEQVIO
What excipients (inactive ingredients) are in LEQVIO?	LEQVIO excipients list
DailyMed Link:	LEQVIO at DailyMed

See drug prices for LEQVIO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LEQVIO

Constraining patent/regulatory exclusivity:

10,125,369

NDA:

214012

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LEQVIO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Louisville	PHASE4
Novartis Pharmaceuticals	Phase 4
Monash University	Phase 4

See all LEQVIO clinical trials

Paragraph IV (Patent) Challenges for LEQVIO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEQVIO	Injection	inclisiran sodium	284 mg/1.5 mL	214012	1	2025-12-22

US Patents and Regulatory Information for LEQVIO

LEQVIO is protected by twenty-six US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,125,369.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021		RX	Yes	Yes
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021		RX	Yes	Yes	10,125,369		Y	Y
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021		RX	Yes	Yes	8,222,222
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021		RX	Yes	Yes	8,809,292		Y	Y

Expired US Patents for LEQVIO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021	9,074,213
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021	10,590,418
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021	8,546,143
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021	10,266,825

International Patents for LEQVIO

When does loss-of-exclusivity occur for LEQVIO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LEQVIO around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2022000433	プロタンパク質転換酵素サブチリシン／ケキシン（ＰＣＳＫ９）遺伝子関連障害を治療するための方法および組成物 (METHOD AND COMPOSITION FOR TREATING DISORDER RELATED TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN (PCSK9) GENE)
Australia	4222993
Germany	69431564
European Patent Office	1430157	INHIBITION DE L'EXPRESSION DU GENE DU VIRUS DE L'HEPATITE C (VHC) INDUITE PAR L'INTERFERENCE D'ARN AU MOYEN D'ACIDE NUCLEIQUE INTERFERANT COURT (SINA) (RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA))

Supplementary Protection Certificates for LEQVIO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2929031	C202130028	Spain		PRODUCT NAME: INCLISIRAN; NATIONAL AUTHORISATION NUMBER: EU/1/20/1494; DATE OF AUTHORISATION: 20201209; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1494; DATE OF FIRST AUTHORISATION IN EEA: 20201209
2929031	LUC00209	Luxembourg		PRODUCT NAME: INCLISIRAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1494 20201210
2929031	C02929031/01	Switzerland		PRODUCT NAME: INCLISIRAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67836 09.09.2021
2929031	C20210012 00398	Estonia		PRODUCT NAME: INKLISIRAAN;REG NO/DATE: EU/1/20/1494 10.12.2020

LEQVIO (inclisiran): Market dynamics and financial trajectory

Last updated: April 24, 2026

What is LEQVIO and what market is it addressing?

LEQVIO (inclisiran) is an siRNA therapeutic for lowering LDL-C in patients at high cardiovascular risk. It is administered by healthcare professionals via subcutaneous injection on a defined schedule (initial dosing then periodic dosing). The commercial opportunity is the secondary prevention and high-risk primary prevention segments where sustained LDL-C lowering affects event rates.

Key market logic

• Chronic, high-value cardiovascular prevention creates recurring demand because patients need durable LDL-C reduction.
• Payer and guideline alignment drive uptake: coverage tends to concentrate in patients meeting high-risk criteria (often alongside statin therapy or when additional LDL-C reduction is needed).
• Device-anchored dosing (clinic-based administration) reduces patient self-administration switching risk versus purely oral competitors but increases site-of-care friction.

How has the competitive landscape shaped LEQVIO pricing, access, and uptake?

LEQVIO competes primarily in the LDL-C lowering market with:

• PCSK9 monoclonal antibodies (e.g., alirocumab, evolocumab) already embedded in payer pathways for high-risk patients.
• Ezetimibe and bempedoic acid as lower-cost add-ons or alternatives in some formularies.
• Statin optimization as baseline therapy.

Implications for market dynamics

• Uptake depends on payer placement: Where LEQVIO gets routed into preferred tiers and prior authorization pathways, volume rises faster.
• Switching is constrained by patient and clinician inertia: Patients stable on PCSK9 mAbs may not switch unless LEQVIO offers clear access or clinical/operational advantage in a given payer plan.
• Clinical differentiation impacts formulary negotiations: Dosing frequency and real-world adherence advantages can support formulary adoption even if headline LDL-C lowering is comparable.

What is the observed financial trajectory for LEQVIO?

LEQVIO revenue is tied to uptake velocity (new starts and persistence) and payer coverage breadth, with seasonality driven by prescription processing and clinic administration cadence.

What’s driving the trajectory

• Patient starts track with the expansion of reimbursement, guideline penetration, and clinician adoption in high-risk cohorts.
• Persistence depends on dosing adherence to the maintenance schedule and continuity of care through cardiology and lipid clinics.
• Share shifts vs PCSK9 mAbs are slower than first-market adoption because payers often manage within-class sequencing, and patients who already qualify frequently remain on established therapy unless a clear benefit or cost advantage emerges.

What to watch in quarterly earnings

• New patient growth indicators: changes in script volume and injection cadence.
• Geographic expansion: revenue splits by major markets often determine growth rates because reimbursement conditions differ by country.
• Net price effects: list price is less important than realized pricing after rebates, managed entry agreements, and tender outcomes.

Where is demand most sensitive: geography, payer policy, or patient selection?

LEQVIO demand sensitivity typically concentrates in three levers:

1) Payer policy (coverage and prior authorization)

• Plans that require strict eligibility criteria limit volume until documentation and outcomes pathways are streamlined.
• Managed entry agreements can shape realized pricing and can delay volume recognition if uptake triggers are tightly managed.

2) Patient selection (high cardiovascular risk criteria)

• Uptake accelerates when clinicians can meet eligibility with standard documentation.
• Uptake slows when the patient must have additional failure/insufficiency documentation beyond common routine practice.

3) Geography (country reimbursement timing and tender structure)

• Launch timing and reimbursement decisions across Europe and other regions often create uneven growth phases.

How do dosing schedule and administration model affect commercialization?

LEQVIO’s clinic administration model drives commercialization mechanics:

• Operational capacity at treatment sites influences patient throughput (especially early after reimbursement).
• Clinician adoption curves matter because lipid specialists and cardiologists must integrate injection workflows into chronic care pathways.
• Persistence is more controllable than oral regimens: clinic scheduling reduces patient nonadherence, which supports stable ongoing demand.

What is the likely revenue composition: new starts vs maintenance?

LEQVIO revenue generally matures through:

• Front-loaded starts after coverage milestones (new eligible patients initiating therapy).
• Ongoing maintenance that becomes dominant as a treated base accumulates.
• Churn exists but tends to be lower where continuity of care systems are strong.

Net effect on financial trajectory

• Early periods are driven by adoption ramps.
• Later periods show more stable growth as the base expands, unless payer policy changes or competition intensifies.

How does competition impact medium-term financial outlook?

Competitive dynamics that typically pressure revenue growth:

• Aggressive payer tiering that keeps the lowest-cost option preferred, limiting within-class share transfers.
• Price pressure due to mAb competition and biosimilar impacts in some regions.
• Sequencing rules: payers may require that patients do not qualify for LEQVIO until after certain prior therapies.

What tends to support revenue growth:

• Real-world persistence advantage from clinic dosing and standardized schedules.
• Expansion of eligibility via guideline adoption and payer policy revisions.
• Tender outcomes that improve realized pricing and accelerate inclusion in hospital formularies.

What is the investment-grade way to frame LEQVIO’s financial story?

A practical financial frame for LEQVIO’s trajectory uses four variables:

1. Eligible patient pool expansion
   • Depends on reimbursement criteria and guideline uptake.
2. Within-class share transfer
   • Driven by switching rates and managed entry rules.
3. Realized net price
   • Influenced by rebates, discounts, and tender outcomes.
4. Persistence
   • Strongly affected by the dosing workflow and clinic scheduling.

If these four variables move favorably, LEQVIO revenue grows faster and holds margins better. If any one deteriorates, growth slows while price/mix pressures intensify.

Key market and financial checkpoints

Commercial milestones that usually precede inflection

• Positive reimbursement decisions and expanded formulary inclusion.
• Broadening of label-supported use within the high-risk cardiovascular categories.
• Expanded contracting with payers that reduce administrative friction.

Milestones that usually precede deceleration

• Tightening of eligibility criteria.
• Tender cycles that push down realized price.
• Increased within-class competition with favorable payer placement for alternatives.

Key Takeaways

• LEQVIO’s market dynamics hinge on payer placement, patient eligibility documentation, and persistence from clinic-based dosing.
• Financial trajectory typically follows a two-phase pattern: adoption-driven new starts early, then a maintenance-heavy revenue profile as the treated base accumulates.
• Competition with PCSK9 mAbs most directly affects share transfer pace and realized net pricing through formulary tiering and sequencing rules.
• Medium-term revenue growth depends on four variables: eligible pool expansion, within-class share transfer, realized net price, and persistence.

FAQs

1. Is LEQVIO revenue more dependent on new patient starts or ongoing maintenance?
   It shifts toward ongoing maintenance as the treated base accumulates; early growth relies more on new starts.

2. What most affects payer access for LEQVIO?
   Eligibility criteria (high cardiovascular risk documentation) and prior authorization requirements.

3. How does LEQVIO’s clinic dosing model influence commercial performance?
   It tends to improve persistence through scheduled administration but requires site operational capacity.

4. What is LEQVIO’s primary commercial threat?
   Within-class competition, especially payer-preferred placement of PCSK9 monoclonal antibodies and any price concessions they secure.

5. What are the leading indicators of LEQVIO revenue trajectory?
   Changes in eligible adoption, injection throughput, and realized net pricing across major geographies.

References

[1] Bloomberg Industry reports and company financial disclosures.
[2] European public assessment documents and product labeling for LEQVIO (inclisiran).
[3] Company earnings releases and investor presentations for inclisiran (LEQVIO) revenue reporting.